Cargando…
Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunom...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764081/ https://www.ncbi.nlm.nih.gov/pubmed/31616387 http://dx.doi.org/10.3389/fmicb.2019.02097 |
_version_ | 1783454301683712000 |
---|---|
author | Guerra-De-Blas, Paola Del Carmen Bobadilla-Del-Valle, Miriam Sada-Ovalle, Isabel Estrada-García, Iris Torres-González, Pedro López-Saavedra, Alejandro Guzmán-Beltrán, Silvia Ponce-de-León, Alfredo Sifuentes-Osornio, José |
author_facet | Guerra-De-Blas, Paola Del Carmen Bobadilla-Del-Valle, Miriam Sada-Ovalle, Isabel Estrada-García, Iris Torres-González, Pedro López-Saavedra, Alejandro Guzmán-Beltrán, Silvia Ponce-de-León, Alfredo Sifuentes-Osornio, José |
author_sort | Guerra-De-Blas, Paola Del Carmen |
collection | PubMed |
description | Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunomodulatory, anti-inflammatory and antimicrobial effects. Although there is evidence that statins may contribute to the containment of Mycobacterium tuberculosis infection, their effects on peripheral blood mononuclear cells (PBMCs) involved in the immune response have not been previously described. Using PBMCs from 10 healthy subjects infected with M. tuberculosis H37Rv, we analyzed the effects of simvastatin on the treatment of the infections in an in vitro experimental model. Direct quantification of M. tuberculosis growth (in CFU/mL) was performed. Phenotypes and cell activation were assessed via multi-color flow cytometry. Culture supernatant cytokine levels were determined via cytokine bead arrays. The induction of apoptosis and autophagy was evaluated via flow cytometry and confocal microscopy. Simvastatin decreased the growth of M. tuberculosis in PBMCs, increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant reduction in bacterial load. We also observed an increase in IL-10 production. We did not observe any direct antimycobacterial activity. This study provides new insight into the mechanism through which simvastatin reduces the mycobacterial load in infected PBMCs. These results demonstrate that simvastatin activates several immune mechanisms that favor the containment of M. tuberculosis infection, providing relevant evidence to consider statins as candidates for host-directed therapy. They also suggest that future studies are needed to define the roles of statin-induced anti-inflammatory mechanisms in tuberculosis treatment. |
format | Online Article Text |
id | pubmed-6764081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67640812019-10-15 Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis Guerra-De-Blas, Paola Del Carmen Bobadilla-Del-Valle, Miriam Sada-Ovalle, Isabel Estrada-García, Iris Torres-González, Pedro López-Saavedra, Alejandro Guzmán-Beltrán, Silvia Ponce-de-León, Alfredo Sifuentes-Osornio, José Front Microbiol Microbiology Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunomodulatory, anti-inflammatory and antimicrobial effects. Although there is evidence that statins may contribute to the containment of Mycobacterium tuberculosis infection, their effects on peripheral blood mononuclear cells (PBMCs) involved in the immune response have not been previously described. Using PBMCs from 10 healthy subjects infected with M. tuberculosis H37Rv, we analyzed the effects of simvastatin on the treatment of the infections in an in vitro experimental model. Direct quantification of M. tuberculosis growth (in CFU/mL) was performed. Phenotypes and cell activation were assessed via multi-color flow cytometry. Culture supernatant cytokine levels were determined via cytokine bead arrays. The induction of apoptosis and autophagy was evaluated via flow cytometry and confocal microscopy. Simvastatin decreased the growth of M. tuberculosis in PBMCs, increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant reduction in bacterial load. We also observed an increase in IL-10 production. We did not observe any direct antimycobacterial activity. This study provides new insight into the mechanism through which simvastatin reduces the mycobacterial load in infected PBMCs. These results demonstrate that simvastatin activates several immune mechanisms that favor the containment of M. tuberculosis infection, providing relevant evidence to consider statins as candidates for host-directed therapy. They also suggest that future studies are needed to define the roles of statin-induced anti-inflammatory mechanisms in tuberculosis treatment. Frontiers Media S.A. 2019-09-20 /pmc/articles/PMC6764081/ /pubmed/31616387 http://dx.doi.org/10.3389/fmicb.2019.02097 Text en Copyright © 2019 Guerra-De-Blas, Bobadilla-Del-Valle, Sada-Ovalle, Estrada-García, Torres-González, López-Saavedra, Guzmán-Beltrán, Ponce-de-León and Sifuentes-Osornio. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Guerra-De-Blas, Paola Del Carmen Bobadilla-Del-Valle, Miriam Sada-Ovalle, Isabel Estrada-García, Iris Torres-González, Pedro López-Saavedra, Alejandro Guzmán-Beltrán, Silvia Ponce-de-León, Alfredo Sifuentes-Osornio, José Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title | Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title_full | Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title_fullStr | Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title_full_unstemmed | Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title_short | Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis |
title_sort | simvastatin enhances the immune response against mycobacterium tuberculosis |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764081/ https://www.ncbi.nlm.nih.gov/pubmed/31616387 http://dx.doi.org/10.3389/fmicb.2019.02097 |
work_keys_str_mv | AT guerradeblaspaoladelcarmen simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT bobadilladelvallemiriam simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT sadaovalleisabel simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT estradagarciairis simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT torresgonzalezpedro simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT lopezsaavedraalejandro simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT guzmanbeltransilvia simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT poncedeleonalfredo simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis AT sifuentesosorniojose simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis |